Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharmacol Exp Ther ; 322(2): 619-30, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17470643

ABSTRACT

The bradykinin B(1) receptor plays a critical role in chronic pain and inflammation, although efforts to demonstrate efficacy of receptor antagonists have been hampered by species-dependent potency differences, metabolic instability, and low oral exposure of current agents. The pharmacology, pharmacokinetics, and analgesic efficacy of the novel benzamide B(1) receptor antagonist 7-chloro-2-[3-(9-pyridin-4-yl-3,9-diazaspiro[5.5]undecanecarbonyl)phenyl]-2,3-dihydro-isoindol-1-one (ELN441958) is described. ELN441958 competitively inhibited the binding of the B(1) agonist ligand [(3)H]desArg(10)-kallidin ([(3)H]DAKD) to IMR-90 human fibroblast membranes with high affinity (K(i) = 0.26 +/- 0.02 nM). ELN441958 potently antagonized DAKD (but not bradykinin)-induced calcium mobilization in IMR-90 cells, indicating that it is highly selective for B(1) over B(2) receptors. Antagonism of agonist-induced calcium responses at B(1) receptors from different species indicated that ELN441958 is selective for primate over rodent B(1) receptors with a rank order potency (K(B), nanomolar) of human (0.12 +/- 0.02) approximately rhesus monkey (0.24 +/- 0.01) > rat (1.5 +/- 0.4) > mouse (14 +/- 4). ELN441958 had good permeability and metabolic stability in vitro consistent with high oral exposure and moderate plasma half-lives in rats and rhesus monkeys. Because ELN441958 is up to 120-fold more potent at primate than at rodent B(1) receptors, it was evaluated in a primate pain model. ELN441958 dose-dependently reduced carrageenan-induced thermal hyperalgesia in a rhesus monkey tail-withdrawal model, with an ED(50) approximately 3 mg/kg s.c. Naltrexone had no effect on the antihyperalgesia produced by ELN441958, indicating a lack of involvement of opioid receptors. ELN441958 is a novel small molecule bradykinin B(1) receptor antagonist exhibiting high oral bioavailability and potent systemic efficacy in rhesus monkey inflammatory pain.


Subject(s)
Analgesics/pharmacology , Bradykinin B1 Receptor Antagonists , Spiro Compounds/pharmacology , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Analgesics/chemistry , Analgesics/pharmacokinetics , Animals , Bradykinin/analogs & derivatives , Bradykinin/pharmacology , Calcium/metabolism , Carrageenan/toxicity , Cell Line , Cell Membrane Permeability , Fibroblasts/cytology , Fibroblasts/drug effects , Fibroblasts/metabolism , Humans , Hyperalgesia/chemically induced , Hyperalgesia/drug therapy , Kallidin/analogs & derivatives , Kallidin/metabolism , Kallidin/pharmacology , Macaca mulatta , Mice , Mice, Knockout , Microsomes, Liver/metabolism , Molecular Structure , Naltrexone/pharmacology , Naproxen/pharmacology , Naproxen/therapeutic use , Narcotic Antagonists , Rats , Receptor, Bradykinin B1/genetics , Receptor, Bradykinin B1/metabolism , Species Specificity , Spiro Compounds/chemistry , Spiro Compounds/pharmacokinetics , Transfection
2.
J Proteome Res ; 5(4): 1017-23, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16602711

ABSTRACT

Prodynorphin-derived peptides elicit various pathological effects including neurological dysfunction and cell death. These actions are reduced by N-methyl-d-aspartate receptor (NMDAR) but not opioid receptor antagonists suggesting NMDAR-mediation. Here, we show that a conserved epitope (KVNSEEEEEDA) of the NR1 subunit of the NMDAR binds dynorphin peptides (DYNp) noncovalently. Synthetic peptides containing this epitope form stable complexes with DYNp and prevent the potentiation of NMDAR-gated currents produced by DYNp. They attenuate DYNp-evoked cell death in spinal cord and prevent, as well as reverse, DYNp-induced paralysis and allodynia. The data reveal a novel mechanism whereby prodynorphin-derived peptides facilitate NMDAR function and produce neurotoxicity. Furthermore, they suggest that synthetic peptides that bind DYNp, thus preventing their interaction with NMDAR, may be novel therapeutic agents for the treatment of spinal cord injury.


Subject(s)
Dynorphins/metabolism , Neuroprotective Agents/metabolism , Neurotoxicity Syndromes/prevention & control , Peptides/metabolism , Receptors, N-Methyl-D-Aspartate/metabolism , Amino Acid Sequence , Animals , Apoptosis/drug effects , Behavior, Animal/drug effects , Cells, Cultured , Conserved Sequence , Electrophysiology , Female , Ganglia, Spinal/cytology , Ganglia, Spinal/drug effects , Ganglia, Spinal/embryology , Immunohistochemistry , Male , Mice , Mice, Inbred ICR , Microinjections , Models, Molecular , Molecular Sequence Data , Neuroprotective Agents/chemistry , Neuroprotective Agents/pharmacology , Nuclear Magnetic Resonance, Biomolecular , Oocytes/metabolism , Paralysis/chemically induced , Peptides/chemistry , Peptides/pharmacology , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Spinal Cord/drug effects , Spinal Cord/metabolism , Spinal Cord/pathology , Time Factors , Xenopus
3.
J Neurosci ; 22(3): 1010-9, 2002 Feb 01.
Article in English | MEDLINE | ID: mdl-11826129

ABSTRACT

Serotonin is a major component of the inflammatory chemical milieu and contributes to the pain of tissue injury via an action on multiple receptor subtypes. Here we studied mice after genetic or pharmacological disruption of the 5-HT(3) receptor, an excitatory serotonin-gated ion channel. We demonstrate that tissue injury-induced persistent, but not acute, nociception is significantly reduced after functional elimination of this receptor subtype. Specifically, in the setting of tissue injury, the 5-HT(3) receptor mediates activation of nociceptors but does not contribute to injury-associated edema. This result is explained by the localization of 5-HT(3) receptor transcripts to a previously uncharacterized subset of myelinated and unmyelinated afferents, few of which express the proinflammatory neuropeptide substance P. Finally, we provide evidence that central serotonergic circuits modulate nociceptive transmission via a facilitatory action at spinal 5-HT(3) receptors. We conclude that activation of both peripheral and central 5-HT(3) receptors is pronociceptive and that the contribution of peripheral 5-HT(3) receptors involves a novel complement of primary afferent nociceptors.


Subject(s)
Nerve Fibers, Myelinated/metabolism , Nociceptors/metabolism , Pain/metabolism , Receptors, Serotonin/metabolism , Animals , Autoradiography , Behavior, Animal/physiology , Cells, Cultured , Mice , Mice, Inbred Strains , Mice, Mutant Strains , Nerve Fibers/metabolism , Nociceptors/cytology , Pain/genetics , Pain Measurement , Protein Subunits , Radioligand Assay , Receptors, Serotonin/deficiency , Receptors, Serotonin/genetics , Receptors, Serotonin, 5-HT3 , Serotonin/metabolism , Stem Cells/cytology , Stem Cells/metabolism , Transfection
4.
Pain ; 94(3): 245-253, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11731061

ABSTRACT

A variety of second messenger systems have been implicated in the intracellular mechanisms of tolerance development to the analgesic actions of morphine, a mu opioid, and clonidine, an alpha-2 adrenergic receptor agonist. Here, we studied mice that carry a null mutation in the gene encoding a neuronal specific isoform of protein kinase C (PKC), namely, PKC gamma. We used the tail-flick test to construct dose-response curves before and 4 days after chronic morphine (75-mg pellets, subcutaneously (s.c.)) or clonidine treatment (0.3mg/kg, s.c., twice daily). Baseline tail-flick latencies did not differ in PKC gamma mutant and wild-type mice (3-4s). Both morphine and clonidine produced a dose-dependent suppression of the tail-flick response with an ED(50) (effective dose resulting in a 50% reduction of the control response) value (2.0mg/kg for morphine and 0.1mg/kg for clonidine) that was similar for naive mutant and wild-type mice. In contrast, after 4 days of drug delivery, mutant mice showed significantly less rightward shift in the dose-response curve to morphine (six-fold for wild-type and three-fold for mutant mice) and to clonidine (five-fold for wild-type and no shift for the mutant mice). These results indicate that PKC gamma contributes to the development of tolerance to the analgesic effects of both morphine and clonidine. Chronic morphine treatment can also result in sensitization of spinal cord neurons and increased pain behaviors following a noxious insult. To assess the contribution of PKC gamma to this process, we studied the responses of wild-type and mutant mice to an intraplantar injection of formalin (a model of persistent pain) following chronic morphine treatment. Although morphine tolerance increased formalin-evoked persistent pain behavior and Fos-LI in wild-type mice, there was no difference between placebo- and morphine-treated mutant mice, suggesting that PKC gamma also contributes to chronic morphine-induced changes in nociceptive processing.


Subject(s)
Analgesics, Opioid/pharmacology , Analgesics/pharmacology , Clonidine/pharmacology , Isoenzymes/genetics , Morphine/pharmacology , Protein Kinase C/genetics , Animals , Drug Tolerance/genetics , Hyperalgesia/drug therapy , Male , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Morphine Dependence/enzymology , Morphine Dependence/genetics , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Pain Measurement/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...